Cyclooxygenase-2-prostaglandin e2-eicosanoid receptor inflammatory axis: A key player in Kaposi's sarcoma-associated herpes virus associated malignancies

Keyphrases

• Cyclooxygenase-2 100%
• Eicosanoids 100%
• Prostaglandin E2 100%
• Kaposi's Sarcoma-associated Herpesvirus 100%
• Virus-associated Malignancies 100%
• EP Receptors 66%
• Kaposi Sarcoma 33%
• Primary Effusion Lymphoma 25%
• VFLIP 25%
• Prostate Cancer 16%
• Latency 16%
• Non-steroidal Anti-inflammatory Drugs (NSAIDs) 16%
• Malignancy 16%
• Viral 16%
• Latency-associated nuclear Antigen 16%
• Molecular Mechanism 8%
• Biological Significance 8%
• Receptor Signaling 8%
• Viral Proteins 8%
• Colon Cancer 8%
• Endothelial Cells 8%
• Lipid Metabolites 8%
• Cell Proliferation 8%
• Cell Tumor 8%
• B Cells 8%
• Receptor Activation 8%
• Therapeutic Modalities 8%
• Signaling Cascades 8%
• Adhesion 8%
• Mechanistic Aspects 8%
• Angiogenesis 8%
• Interferon-α (IFN-α) 8%
• Beta-blockers 8%
• Apoptotic Cells 8%
• Pharmacologic Agents 8%
• Blockage 8%
• Inhibitory Proteins 8%
• Therapeutic Target 8%
• Cervical Cancer 8%
• Tumorigenic Potential 8%
• Immune Suppression 8%
• Cancer Colon 8%
• Nasopharyngeal Carcinoma 8%
• Burkitt Lymphoma 8%
• Biological Mechanisms 8%
• Cell Cycle Regulation 8%
• Cardiovascular Toxicity 8%
• Antineoplastic Agents 8%
• Active Area 8%
• HHV-8 8%
• Lymphomagenesis 8%
• Gastrointestinal Toxicity 8%
• Paracrine Interactions 8%
• Death Domain 8%
• Proliferative Disorder 8%
• Enzyme-like 8%
• EP-1 8%

Medicine and Dentistry

• Cancer 100%
• Cyclooxygenase 2 100%
• Herpesviridae 100%
• Prostaglandin E2 100%
• Kaposi Sarcoma 100%
• Eicosanoid Receptor 100%
• Receptor 66%
• Primary Effusion Lymphoma 25%
• Secretion (Process) 16%
• Nonsteroid Antiinflammatory Agent 16%
• Latency Associated Nuclear Antigen 16%
• Neoplasm 8%
• Angiogenesis 8%
• Programmed Cell Death 8%
• Infection 8%
• Prostate Cancer 8%
• Endothelial Cell 8%
• Interferon 8%
• Viral Protein 8%
• Therapeutic Modality 8%
• Immunosuppressive Treatment 8%
• Icosanoid 8%
• Cervical Cancer 8%
• B Cell 8%
• Cell Cycle Regulation 8%
• Nasopharynx Carcinoma 8%
• Burkitt's Lymphoma 8%
• Antineoplastic Activity 8%
• Colon Carcinoma 8%
• Dipeptidyl Carboxypeptidase 8%
• Cardiovascular Toxicity 8%
• Gastrointestinal Toxicity 8%
• Lipid Metabolite 8%
• Diseases 8%
• Death Domain Superfamily 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Receptor 100%
• Cyclooxygenase 2 100%
• Prostaglandin E2 100%
• Icosanoid 100%
• Herpesviridae 100%
• Kaposi Sarcoma 100%
• Primary Effusion Lymphoma 25%
• Non-Steroidal Anti-Inflammatory Drug 16%
• Latency Associated Nuclear Antigen 16%
• Infection 8%
• Prostate Cancer 8%
• Neoplasm 8%
• Viral Protein 8%
• Interferon 8%
• Uterine Cervix Cancer 8%
• Cardiovascular Toxicity 8%
• Colon Carcinoma 8%
• Dipeptidyl Carboxypeptidase 8%
• Burkitt's Lymphoma 8%
• Diseases 8%
• Nasopharynx Carcinoma 8%
• Gastrointestinal Toxicity 8%